SCHEMBL16972470

SCHEMBL16972470

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCC(O)CC4)ccc3OCC)nc12

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 0.85
PDE3B Q13370 4/20 0.83
PDE3A Q14432 4/20 0.83
PDE2A O00408 1/20 0.83
ABCC4 O15439 1/20 0.83
ABCC5 O15440 1/20 0.83
PDE6D O43924 1/20 0.83
PDE8A O60658 1/20 0.83
PDE9A O76083 1/20 0.83
ABCB11 O95342 1/20 0.83
CYP3A4 P08684 1/20 0.83
HTR1A P08908 1/20 0.83
PDE6A P16499 1/20 0.83
PDE6G P18545 1/20 0.83
PDE4A P27815 1/20 0.83
ADORA2A P29274 1/20 0.83
ADORA1 P30542 1/20 0.83
ADRA1A P35348 1/20 0.83
PDE6B P35913 1/20 0.83
PDE6C P51160 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24051299 0.93 PDE5A (0.84) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL16972497 0.93 PDE5A (0.84) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL16972455 0.93 PDE5A (0.84) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL18577850 0.93 PDE5A (0.84) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL30848678 0.93 PDE5A (0.95) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL15407059 0.93 PDE5A (0.81) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL16972499 0.92 PDE5A (0.85) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL23370685 0.92 PDE5A (0.80) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL24051291 0.92 PDE5A (0.81) PDE5APDE3BPDE3APDE2AABCC4
SCHEMBL24051300 0.92 PDE5A (0.89) PDE5APDE3BPDE3APDE2AABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017511-B2 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-07-10 US claimed
US-20170066771-A1 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-03-09 US claimed
EP-3099689-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific and Industrial Research (IN) 2016-12-07 EP claimed
WO-2015114647-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-08-06 WO claimed
EP-3099689-B1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2022-01-26 EP disclosed
US-10017511-B2 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-07-10 US disclosed
US-10017511-B2 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-07-10 US disclosed
US-10017511-B2 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-07-10 US disclosed
US-20170066771-A1 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-03-09 US disclosed
US-20170066771-A1 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-03-09 US disclosed
US-20170066771-A1 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-03-09 US disclosed
EP-3099689-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific and Industrial Research (IN) 2016-12-07 EP disclosed
WO-2015114647-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017511-B2 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof PDE5A, PDE3A, PDE3B PDE5A 1/4885PDE3B 3/4885PDE3A 2/4885
US-20170066771-A1 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof PDE5A, PDE3A, PDE3B PDE5A 1/4885PDE3B 3/4885PDE3A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.